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Background: Whilst the 99th percentile is the recommended diagnostic threshold for myocardial 
infarction, some guidelines also advocate the use of higher troponin thresholds to rule-in 
myocardial infarction at presentation. It is unclear whether the magnitude or change in troponin 
concentration can differentiate causes of myocardial injury and infarction in practice. 
Methods: In a secondary analysis of a multi-centre randomized controlled trial, we identified 
46,092 consecutive patients presenting with suspected acute coronary syndrome without ST-
segment elevation myocardial infarction. High-sensitivity cardiac troponin I concentrations at 
presentation and on serial testing were compared between patients with myocardial injury and 
infarction. The positive predictive value (PPV) and specificity were determined at the sex-
specific 99th percentile upper reference limit (URL), and rule-in thresholds of 64 ng/L and 5-fold 
of the URL for a diagnosis of type 1 myocardial infarction.  
Results: Troponin was above the 99th percentile in 8,188 (18%) patients. The diagnosis was type 
1 or type 2 myocardial infarction in 50% and 14%, and acute or chronic myocardial injury in 
20% and 16%, respectively. Troponin concentrations were similar at presentation in type 1 
(median [25th percentile - 75th percentile] 91 [30-493] ng/L) and type 2 (50 [22-147] ng/L) 
myocardial infarction, and in acute (50 [26-134] ng/L) and chronic (51 [31-130] ng/L) 
myocardial injury. The 99th percentile and rule-in thresholds of 64 ng/L and 5-fold URL gave a 
PPV of 57% (95% confidence interval [CI] 56-58%), 59% (58-61%) and 62% (60-64%), and a 
specificity of 96% (96-96%), 96% (96-96%) and 98% (97-98%), respectively. The absolute, 
relative and rate of change in troponin concentration was highest in patients with type 1 
myocardial infarction (P<0.001 for all). Discrimination improved when troponin concentration 
and change in troponin were combined compared to troponin concentration at presentation alone 
(area under curve, 0.661 [0.642-0.680] versus 0.613 [0.594-0.633]). 
Conclusions: Although we observed important differences in the kinetics, cardiac troponin 
concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from 
other causes of myocardial injury or infarction in practice and should not guide management 
decisions in isolation. 
Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: 
NCT01852123 
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Non-standard abbreviaitons and acronyms:  
PPV positive predictive value 
NPV negative predictive value 
ESC European Society of Cardiology 
URL upper reference limit 
ng/L nanograms per litre 
g/L grams per litre 
CABG coronary artery bypass grafting 
PCI percutaneous coronary intervention 
  
   
  










What is new? 
• In 46,092 consecutive patients with suspected acute coronary syndrome we evaluated the 
performance of the 99th percentile rule-in threshold, and thresholds of 64 ng/L and 5-
times the upper reference limit, for the diagnosis of type 1 myocardial infarction. 
• Troponin concentrations at presentation have a low positive predictive value for type 1 
myocardial infarction, and a threshold 50-times the upper reference limit is required to 
achieve a positive predictive value ≥70%. 
• Change in troponin on serial testing only marginally improves positive predictive value 
for type 1 myocardial infarction over presenting troponin alone (area under curve, 0.661 
[0.642 to 0.680] versus 0.613 [0.594 to 0.633]) 
 
What are the clinical implications? 
• Troponin concentrations at presentation are insufficient to distinguish type 1 myocardial 
infarction from other causes of myocardial injury or infarction and should not be used in 
isolation to guide management decisions in patients with suspected acute coronary 
syndrome. 
• Consideration of other important clinical factors may be more helpful than any rule-in 










To promote adoption of common standards, the Universal Definition of Myocardial Infarction 
recommends cardiac troponin testing and the 99th percentile upper reference limit (URL) as the 
diagnostic threshold for myocardial infarction.1 In practice, there are many causes of troponin 
elevation, with around half of all increases due to conditions other than type 1 myocardial 
infarction.2–9 Nonetheless, the early differentiation between types of myocardial infarction and 
acute or chronic non-ischemic myocardial injury is important as the immediate management of 
these conditions differs.1,10,11 Prompt treatment with anti-platelet agents, anti-coagulation and 
coronary revascularisation is recommended in type 1 myocardial infarction, where these may not 
be indicated in type 2 myocardial infarction or myocardial injury, and indeed may be 
contraindicated.8,12  
Alternative thresholds above the 99th percentile have been proposed to improve the 
positive predictive value (PPV) and specificity of troponin for type 1 myocardial infarction.11,13–
16 The European Society of Cardiology guidelines propose the use of rule-in thresholds above the 
99th percentile to guide admission to cardiology and coronary angiography.11 These rule-in 
thresholds and those five-times the URL are purported to give a PPV of at least 70% and 90%, 
resepectively.11 They were derived in selected patients with chest pain, but in practice troponin 
testing is applied more widely to evaluate patients with suspected acute coronary syndrome 
presenting with a broader range of symptoms.3,17 Guidelines also recommend serial testing with a 
rise or fall in cardiac troponin needed to confirm the diagnosis of myocardial infarction.1,10,11,18 
However, patients with type 2 myocardial infarction and acute non-ischemic myocardial injury 
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rule-in thresholds or troponin kinetics can reliably differentiate between types of myocardial 
infarction or between myocardial injury and infarction in clinical practice.22 
 Our aim was to evaluate the performance of recommended cardiac troponin thresholds to 
rule-in the diagnosis of type 1 myocardial infarction at presentation. We also sought to determine 
whether the kinetics of cardiac troponin differs sufficiently to discriminate between myocardial 
injury and infarction.23  
 
Methods 
Transparency and openness promotion  
The High-Sensitivity Troponin in the Evaluation of Patients with Suspected Acute Coronary 
Syndrome (High-STEACS) trial makes use of multiple routine electronic health care data 
sources that are linked, deidentified, and held in a national safe haven, which is accessible by 
approved individuals who have undertaken the necessary governance training. Summary data 
and the analysis code can be made available upon request from the corresponding author. 
Study population and trial design  
High-STEACS is a stepped-wedge cluster randomized, controlled trial that evaluated the 
implementation of a high-sensitivity cardiac troponin I assay in consecutive patients with 
suspected acute coronary syndrome across 10 secondary and tertiary care hospitals in Scotland. 
A detailed description of this trial has been reported elsewhere,2 but in summary, all patients 
attending the Emergency Department were screened for suspected acute coronary syndrome by 
the attending clinician at the time cardiac troponin was requested, using an electronic form 
integrated into the clinical care pathway. Patients were eligible for inclusion if they presented 
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standard care and trial assay. Patients were excluded if they had been admitted previously during 
the trial period or were not resident in Scotland. In this analysis, we excluded patients with ST-
segment elevation myocardial infarction,24 where troponin concentration at presentation was 
missing, or where the adjudicators were unable to arrive at a consensus for the final diagnosis.  
Measurement of cardiac troponin 
Cardiac troponin testing was performed at presentation to hospital and was repeated 6 or 12 
hours after the onset of symptoms at the discretion of the attending physician in accordance with 
national guidelines.25,26 All patients had troponin measured using a high-sensitivity cardiac 
troponin I assay (ARCHITECTSTAT high-sensitive troponin I assay; Abbott Laboratories, Abbott 
Park, IL, USA). This assay has an inter-assay coefficient of variation of less than 10% at 4.7 
ng/L, and limit of detection of 1.2 ng/L and 1.9 ng/L. For consistency with prior studies, we 
defined the limit of detection as any concentration <2 ng/L and for the purpose of this analysis 
assigned concentrations below the limit of detection a value of 1.0 ng/L.27,28 The assay has a 99th 
percentile URL of 26 ng/L, with sex-specific thresholds of 34 ng/L and 16 ng/L in men and 
women, respectively.29,30  
Diagnostic adjudication   
All patients with any high-sensitivity cardiac troponin I concentration above the sex-specific 99th 
percentile were adjudicated and classified according to the Fourth Universal Definition of 
Myocardial Infarction.1 Two physicians independently reviewed all clinical information, with 
discordant diagnoses resolved by a third physician. Type 1 myocardial infarction was defined as 
myocardial necrosis (any high-sensitivity cardiac troponin I concentration above the sex-specific 
99th percentile with a rise or fall in troponin where serial testing was performed) in the context of 
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ischemia on the electrocardiogram. Patients with myocardial necrosis, symptoms or signs of 
myocardial ischemia, and evidence of myocardial oxygen supply-demand imbalance secondary 
to an alternative condition without evidence of acute atherothrombosis were classified as type 2 
myocardial infarction.21 Patients with elevated troponin concentrations without symptoms or 
signs of myocardial ischemia were classified as having non-ischemic myocardial injury. All non-
ischemic myocardial injury was classified as acute, unless troponin concentrations changed 
≤20% on serial testing in accordance with the Universal Definition, or if the adjudicated 
diagnosis was chronic heart failure or chronic renal failure, where the classification was chronic 
myocardial injury. A detailed summary of the adjudication procedures is provided in the 
Supplemental Material. 
Ethical approval  
The study was approved by the Scotland A Research Ethics Committee, the Public Benefit and 
Privacy Panel for Health and Social Care, and by each National Health Service Health Board. 
Individual patient consent was not required and data from consecutive patients was collected 
prospectively from the electronic record, deidentified and linked within secure National Health 
Service Safe Havens.  
Patient and public involvement 
Patients and lay representatives were members of the steering committee for the trial and all 
related studies and were involved in the design, conduct and approval of the High-STEACS 
study. 
Statistical Analysis  
Baseline characteristics were summarized for the study population and in groups according to the 
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myocardial injury, chronic myocardial injury and no myocardial injury. Group wise comparisons 
were performed using χ2, Kruskal–Wallis or one-way analysis of variance (one-way ANOVA) 
tests as appropriate. We constructed confusion matrices and calculated the PPV and specificity 
for type 1 myocardial infarction of a high-sensitivity cardiac troponin I concentration at 
presentation above the uniform 99th percentile (26 ng/L), sex-specific 99th percentile (16 ng/L in 
women, 34 ng/L in men), guideline recommended rule-in threshold of 64 ng/L, and 3-fold and 5-
fold URL thresholds (78 and 130 ng/L, respectively). Based on prior literature we also 
determined the cardiac troponin concentration at presentation that met a pre-specified PPV of 
75%.31 We calculated the 95% confidence interval (CI) using a Bayesian approach by sampling 
from a binomial likelihood with noninformative Jeffreys prior (ß-distribution shape parameters 
both equal to 0.5). In a sensitivity analysis, we evaluated the PPV and specificity in patients 
where the primary presenting symptom recorded by the attending clinician was chest pain.  
In patients with serial sampling within 12 hours of presentation we used linear mixed-
effects modelling with random slopes and intercepts to evaluate the relationship between 
symptom onset, troponin and change in troponin concentration. Non-linear associations were 
evaluated by adding a second-order polynomial term for time to the model. We have compared 
the models with and without a quadratic term for time, and the final model was chosen based on 
the lowest Akaike Information Criteria. To illustrate the kinetics of cardiac troponin across the 
groups we developed additional models for each diagnostic classification. Within each of these 
models we included type 2 myocardial infarction or acute or chronic myocardial injury, as a 
fixed effect, with type 1 myocardial infarction as the reference group. To evaluate whether 
relative or absolute change in troponin on serial testing improves discrimination for type 1 
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regression and compared the area under the receiver operating characteristic curve (AUC). We 
evaluated models that incorporated relative and absolute change as continuous measure, and 
absolute and relative delta values of 15 ng/L and 20% as recommended in international 
guidelines.10,11 All analyses were performed in R (Version 3.5.1).  
 
Results 
The analysis population comprised 46,092 of the 48,242 patients enrolled in the trial after 
excluding those with ST-segment elevation myocardial infarction (n=925), those where the 
diagnosis could not be adjudicated (n=1,241), or  those with missing troponin concentrations at 
presentation (n=24), Figure I in the Supplement).  
Cardiac troponin concentrations were above the sex-specific 99th percentile URL in 8,188 
(18%) patients. The adjudicated diagnosis was type 1 myocardial infarction in 50% (n=4,064), 
type 2 myocardial infarction in 14% (n=1,116), acute myocardial injury in 20% (n=1,676), and 
chronic myocardial injury in 16% (n=1,287) of patients (Table 1). Patients with type 1 
myocardial infarction were younger and more likely to be men than those with type 2 myocardial 
infarction or acute and chronic myocardial injury. Chest pain was the primary presenting 
symptom in 90% of patients with type 1 myocardial infarction (3,315/3,692) and 73% in type 2 
(744/1,026) myocardial infarction, but was less common in patients with acute (38%, 569/1,495) 
or chronic (49%, 559/1,131) myocardial injury. 
Troponin concentrations at presentation in myocardial injury and infarction 
At presentation, troponin concentrations were similar in type 1 (median [25th percentile to 75th 
percentile] 91 [30 to 493] ng/L) and type 2 (50 [22 to 147] ng/L) myocardial infarction, and in 
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1). A troponin concentration above the uniform 99th percentile at presentation gave a PPV of 
48% and specificity of 92% for type 1 myocardial infarction (Table 2). The sex-specific 99th 
percentile of 16 ng/L in women gave a PPV and specificity of 39% and 89%, whereas the sex-
specific 99th percentile of 34 ng/L in men gave a PPV and specificity of 56% and 93%, 
respectively. The rule-in threshold of 64 ng/L and 5-fold URL threshold gave PPVs of 57% and 
62% respectively, with specificities of 96% and 97% (Figure 2). To achieve a PPV of 75% a 
rule-in threshold of 1,303 ng/L was required, whereas no threshold gave a PPV of 90% or above.  
In a sensitivity analysis restricted to 82% (33,319/40,844) of patients in whom the primary 
presenting symptom was chest pain (Table I in the Supplement), the PPV and specificity for 
type 1 myocardial infarction at the rule-in threshold of 64 ng/L was 72% and 98%, respectively 
(Table 2). The 5-fold URL threshold gave a PPV of 75% and a specificity of 99%. A rule-in 
threshold of 119 ng/L gave a PPV of 75%, but no threshold achieved a PPV of 90% in this 
population (Figure 2).  
Troponin kinetics in myocardial injury and infarction 
Serial troponin testing within 12 hours of presentation was performed in 4,187 (51%) patients 
with concentrations above the sex-specific 99th percentile. The time from symptom onset to 
initial troponin sampling was similar in patients with type 1 and type 2 myocardial infarction and 
acute myocardial injury (240 [180 to 420] minutes), but was longer in patients with chronic 
myocardial injury (300 [180 to 780] minutes). The rate of change in troponin within 12 hours of 
presentation was highest in patients with type 1 myocardial infarction, as compared to type 2 
myocardial infarction and acute or chronic myocardial injury (P<0.001 for all, Figure 3). The 
absolute change in troponin concentration differed in patients with type 1 myocardial infarction 
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acute non-ischemic myocardial injury (57 [17 to 384] ng/L) and chronic myocardial injury (6 [2 
to 22] ng/L) (P<0.001 for all Figure 4). The relative change in troponin concentration also 
differed between patients with type 1 myocardial infarction (231 [31 to 1,602] %), as compared 
to as compared to type 2 myocardial infarction (105 [22 to 656] %), acute non-ischemic 
myocardial injury (129 [45 to 534] %), and chronic myocardial injury (12 [5 to 24] %)(P<0.001 
for all).  
Combining troponin concentration at presentation with an absolute change in troponin on 
serial testing of >15 ng/L, or relative change of >20% improved discrimination for type 1 
myocardial infarction compared to troponin concentration at presentation alone (0.646 [0.627 to 




In consecutive patients with suspected acute coronary syndrome we evaluated whether troponin 
concentrations at presentation or their kinetics differed sufficiently to discriminate between 
myocardial injury and infarction. We report a number of observations that are relevant to 
practice. First, troponin concentrations at presentation are similar in patients with myocardial 
injury or infarction regardless of the diagnostic classification. Second, the use of recommended 
rule-in thresholds above the 99th percentile provide only marginal improvements in the PPV and 
specificity for type 1 myocardial infarction. Troponin thresholds >1,000 ng/L would be required 
to achieve a PPV of 75% or more. Third, the magnitude and rate of change of troponin can help 
differentiate type 1 from type 2 myocardial infarction, and acute or chronic myocardial injury. 
Whilst we observed important differences in troponin kinetics, the troponin concentration at 
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presentation provides only limited discrimination between type 1 myocardial infarction and other 
causes of myocardial injury or infarction. Clinical context may be more helpful than any given 
rule-in threshold to guide the triage and initial management of patients with suspected acute 
coronary syndrome in practice. 
In contrast to the previous generation of cardiac troponin assays, high-sensitivity assays 
are able to precisely measure troponin at very low concentrations. Accelerated diagnostic 
pathways that harness this enhanced precision to enable earlier decisions to rule-out and rule-in 
myocardial infarction are now used widely around the world and have been recommended by 
international guidelines.1,11,32,33 The diagnostic performance of these pathways has been 
validated in multiple observational studies,16,34–38 and the effectiveness and safety of ruling out 
myocardial infarction earlier demonstrated in randomized controlled trials.39,40 However, the 
only prior randomized trial to evaluate the effectiveness of applying the 99th percentile to rule-in 
myocardial infarction did not demonstrate better outcomes.41 
The major advantage of accelerated diagnostic pathways using high-sensitivity cardiac 
troponin testing is that they improve confidence to rule out myocardial infarction and reduce the 
need for admission to hospital.24,39,40 However, the use of lower thresholds to diagnose 
myocardial infarction has identified more patients with elevated cardiac troponin concentrations 
due to other conditions.2,3,9 As such, thresholds above the 99th percentile have been proposed to 
improve the specificity and positive predictive value and to accelerate the rule-in of myocardial 
infarction. Assay specific rule-in thresholds are recommended by the European Society of 
Cardiology practice guidelines, which also advocate that patients with troponin concentrations 
above these thresholds at presentation are triaged to a coronary care unit and undergo coronary 
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clinical practice, where testing is often performed in a broader group of patients. Our findings are 
consistent with the concept that underpins these recommendations - the higher the troponin 
concentration at presentation, the higher the likelihood of type 1 myocardial infarction. However, 
the PPV of the rule-in threshold was 57%, and was considerably lower than the 77% and 70% 
reported in the derivation and validation of this rule-in threshold.42 Our observations are 
consistent with a recent study level meta-analysis, which reported that the PPV of the rule-in 
component of a multi-threshold 0/1 hour pathway using a high-sensitivity cardiac troponin T 
assay was 51%.43 However, this was not a patient level analysis, and the performance of the rule-
in threshold in isolation was not reported. Interestingly, when our patient population was 
restricted to the 33,308 patients presenting with a primary symptoms of chest pain to enable 
direct comparison with those studies in which the rule-in threshold was defined, we observed a 
substantial improvement in the PPV to 72%. Taken together these observations highlight the 
importance of interpreting cardiac troponin in context and the merits of evaluating the 
performance of diagnostic tests in the population in which they are applied in practice.  
In consecutive patients with suspected acute coronary syndrome half of all patients with 
elevated cardiac troponin concentrations had a diagnosis of type 2 myocardial infarction or acute 
and and chronic non-ischemic myocardial injury. Our findings are consistent with those from the 
Biomarkers in Acute Cardiac Care (BACC) study where just 29% of patients with an elevated 
cardiac troponin T concentration had a diagnosis of type 1 myocardial infarction.44 Whilst we 
observed that troponin concentrations were higher in type 1 myocardial infarction there was 
substantial overlap with type 2 myocardial infarction and myocardial injury suggesting troponin 
alone at any threshold cannot reliably discriminate between these conditions. Even at a threshold 
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62% for type 1 myocardial infarction. A threshold more than 50-times the URL would be 
required to achieve a PPV of 75% when applied to all patients with suspected acute coronary 
syndrome.  
Whilst our observations highlight the limitations of using single troponin measurements 
to triage patients, confirmation of the diagnosis of myocardial infarction requires serial testing 
and a rise or fall in cardiac troponin.1 We observed differences in the rate of troponin release 
with a higher rate of change, as well as larger absolute and relative changes on serial sampling, 
in patients with type 1 myocardial infarction compared to type 2 myocardial infarction or acute 
and chronic myocardial injury. Despite these differences, the use of relative or absolute delta 
change criteria only marginally improved discrimination compared with the troponin 
concentration alone. This is perhaps not surprising given the observed changes in troponin 
concentration on serial testing in both type 2 myocardial infarction and in acute myocardial 
injury. Whilst previous studies using a contemporary sensitive troponin assay in a small cohort 
of 66 and 188 patients with type 1 and type 2 myocardial infarction, respectively, suggested no 
improvement in discrimination when change in troponin at 3 or 6 hours was combined with the 
absolute concentration,45 we observed a modest improvement. It would seem unlikely that the 
shorter time intervals between serial testing would improve discrimination, but this should be 
evaluated in future studies.   
In recent years a number of approaches have been proposed that could enable clinicians 
to use cardiac troponin more flexibly.31,46,47 These approaches recognize the limitations of 
applying fixed thresholds to triage a heterogenous population of patients and the challenge of 
performing serial testing at precise intervals in clinical practice. The Troponin only-Manchester 





 http://ahajournals.org by on July 2, 2021
10.1161/CIRCULATIONAHA.121.054302 
15 
risk estimates for non-ST-segment elevation myocardial infarction, by incorporating age, sex, 
clinical variables, and a measure of high-sensitivity cardiac troponin T at presentation. The T-
MACS rule performs well, but does not discriminate type 1 myocardial infarction from other 
causes of troponin elevation or take into account serial testing.47 In a collaborative analysis that 
pooled data from multiple cohorts, the Calculation of Myocardial Infarction Risk Probabilities to 
Manage Patients With Suspicion of Myocardial Infarction (COMPASS-MI) investigators 
highlight that a more flexible approach is required and demonstrate proof of concept that the 
negative and positive predictive values for type 1 myocardial infarction vary across a range of 
thresholds and delta change in troponin values.46 Finally, the myocardial-ischemic-injury-index 
(MI3) uses a gradient boosting machine learning algorithm to combine age, sex and paired high-
sensitivity cardiac troponin I values to compute a value (0-100) that reflects the likelihood of 
type 1 myocardial infarction for an individual patient.31 Serial testing can be performed at any 
time point and the algorithm incorporates a measure of rate of change in troponin. Whilst each of 
these approaches show considerable promise it is unclear at present whether the use of these 
probabilistic scores in practice improves clinical decisions compared to existing guideline 
recommended pathways using fixed thresholds.   
We recognize some strengths and limitations of this study. First, we enrolled consecutive 
patients in whom the attending clinician suspected acute coronary syndrome by embedding our 
screening tool into the electronic health care system. This avoided selection bias and ensured that 
our study population was representative. Second, all diagnoses were adjudicated according to the 
Fourth Universal Definition of Myocardial Infarction ensuring our findings are relevant to 
contemporary practice. Whilst few patients had missing troponin values for the evaluation of 
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and was only performed in 53% of patients with myocardial injury or infarction. It is likely that 
those patients undergoing serial testing differed from those who had a single test performed, 
however our comparison between patients with type 1 and type 2 myocardial infarction and those 
with myocardial injury was limited to the subgroup of patients with 2 or more tests performed 
within 12-hours of presentation. Importantly cardiac troponin was measured using a single high-
sensitivity cardiac troponin I assay, and we recognize that the performance of rule-in thresholds 
for myocardial infarction are likely to differ for other assays. Finally, the approach to patient 
selection for cardiac troponin testing will vary across healthcare systems, and we would 
recommend some caution in extrapolating the performance of rule-in thresholds to sites where 
testing is performed more widely.  
In conclusion, although we observed important differences in the kinetics, cardiac 
troponin concentrations at presentation are insufficient to distinguish type 1 myocardial 
infarction from other causes of myocardial injury or infarction in practice. Clinical context may 
be more helpful than any rule-in threshold when guiding initial triage and management decisions. 
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Table 1. Baseline characteristics of study population stratified by adjudicated diagnosis of myocardial injury or infarction  
 
  All participants 
Type 1 myocardial 
infarction 
Type 2 myocardial 
infarction 




No myocardial  
injury 
No. of participants 46,092 4,064 1,116 1,676 1,287 37,904 
Age (years) 61.0 (49.0 - 75.0) 69.0 (58.0 - 80.0) 77.0 (67.0 - 84.0) 78.0 (68.0 - 86.0) 78.0 (65.5 - 85.0) 
58.0 (47.0 - 
71.0) 
Sex (Male) 24,433 (53.0) 2,371 (58.3) 500 (44.8) 664 (39.6) 536 (41.6) 20,341 (53.7) 
Presenting symptoms*       
Chest pain 33,319 (81.6) 3,315 (89.8) 744 (72.5) 569 (38.1) 559 (49.4) 28,091 (84.0) 
Dyspnoea 1,977 (4.8) 146 (4.0) 116 (11.3) 372 (24.9) 235 (20.8) 1,107 (3.3) 
Other 2,003 (4.9) 151 (4.1) 61 (5.9) 217 (14.5) 116 (10.3) 1,458 (4.4) 
Palpitation 1,213 (3.0) 15 (0.4) 67 (6.5) 97 (6.5) 42 (3.7) 991 (3.0) 
Syncope 2,332 (5.7) 65 (1.8) 38 (3.7) 240 (16.1) 179 (15.8) 1,808 (5.4) 
Past medical history        
Coronary artery disease 11,349 (24.6) 1,408 (34.6) 454 (40.7) 509 (30.4) 492 (38.2) 8,444 (22.3) 
Myocardial infarction 4,003 (8.7) 619 (15.2) 163 (14.6) 161 (9.6) 205 (15.9) 2,832 (7.5) 
Diabetes mellitus 3,274 (7.1) 708 (17.4) 147 (13.2) 208 (12.4) 164 (12.7) 2,039 (5.4) 
Cerebrovascular disease 2,732 (5.9) 323 (8.0) 135 (12.1) 192 (11.5) 167 (13.0) 1,914 (5.1) 
Hypercholesterolaemia 18,412 (39.9) 2,1056 (51.8) 631 (56.5) 852 (50.8) 686 (53.3) 14,0926 (37.2) 
Heart failure 3,908 (8.5) 682 (16.8) 291 (26.1) 410 (24.5) 363 (28.2) 2,155(5.7) 
Abnormal renal function 8,398 (18.7) 1,246 (31.2) 536 (49.0) 855 (52.6) 642 (51.6) 5,112 (13.9) 
Previous revascularisation        
PCI 3,543 (7.7) 446 (11.0) 97 (8.7) 94 (5.6) 128 (9.9) 2,743 (7.2) 
CABG 747 (1.6) 101 (2.5) 32 (2.9) 45 (2.7) 34 (2.6) 534 (1.4) 
Electrocardiogram†        
Normal 2,522 (37.3) 1,519 (43.2) 201 (19.6) 400 (34.3) 363 (36.8) - 
Myocardial ischemia 1,740 (25.7) 1,152 (32.8) 379 (36.9) 112 (9.6) 75 (7.6) - 
ST depression 1,185 (17.5) 752 (21.4) 278 (27.0) 87 (7.5) 56 (5.7) - 
ST elevation 243 (3.6) 129 (3.7) 31 (3.0) 38 (3.3) 40 (4.1) - 
T-wave inversion 1,191 (17.6) 733 (20.8) 166 (16.1) 128 (11.0) 148 (15.0) - 
Observations, haematology, and 
clinical chemistry  
      
Systolic blood pressure, mmHg 139.4 (28.9) 143.3 (27.3) 132.4 (29.9) 135.7 (31.2) 137.4 (28.6) 137.5 (23.3) 
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Haemoglobin, g/L 137.2 (18.2) 135.5 (19.7) 127.8 (25.3) 129.7 (21.6) 128.5 (20.6) 138.2 (17.2) 
Presentation troponin, ng/L 3.0 (1.2 - 10.6) 91.0 (30.2 - 492.5) 49.5 (22.0 - 147.2) 50.0 (25.5 - 134.2) 51.1 (30.5 - 130.3) 2.2 (1.0 - 5.1) 
Peak troponin, ng/L 3.6 (1.4 - 12.4) 538.4 (85.0 - 3584.9) 123.8 (48.1 - 599.7) 74.0 (37.1 - 307.1) 55.2 (34.1 - 144.7) 2.6 (1.0 - 6.0) 
Presented as No. (%), mean±SD or median [25th percentile – 75th percentile]. Abbreviations: CABG = coronary artery bypass grafting; PCI = percutaneous coronary 
intervention. *Presenting symptoms are reported for the 87% (40,844/46,092) of patients where primary symptom data was available. † Electrocardiographic data reported 
for the 82% (6,739/8,188) patients with myocardial infarction or myocardial injury who had electrocardiographic data available. ‡ Serial testing was defined as two or mor  
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Table 2. Diagnostic performance of cardiac troponin concentration at presentation in all patients with suspected acute coronary syndrome and in 










PPV (95% CI) NPV (95% CI) Sensitivity (95% CI) Specificity (95% CI) 
All suspected acute coronary syndrome (n=46,068) 
Uniform 99th 
percentile 
26 ng/L 3,191 3,466 38,562 873 47.9 (46.7 to 49.1) 97.8 (97.6 to 97.9) 78.5 (77.2 to 79.8) 91.8 (91.5 to 92.0) 
Sex-specific 
99th percentile 
34 ng/L  
(men) 
1,876 1,500 20,569 492 55.6 (53.9 to 57.3) 97.7 (97.4 to 97.9) 79.2 (77.6 to 80.9) 93.2 (92.9 -93.5) 
16 ng/L  
(women) 
1,463 2,256 17,703 230 39.3 (37.8 to 40.9) 98.7 (98.5 to 98.9) 86.5 (84.87 to 88.0) 88.7 (88.3 -89.1) 
Rule-in*  64 ng/L 2,308 1,734 40,294 1,756 57.1 (55.6 to 58.6) 95.8 (95.6 to 96.0) 56.8 (55.3 to 58.3) 95.9 (95.7 to 96.1) 
3-times URL 78 ng/L 2,161 1,494 40,534 1,903 59.1 (57.5 to 60.7) 95.5 (95.3 to 95.7) 53.2 (51.6 to 54.7) 96.4 (96.3 to 96.6) 
5-times URL 130 ng/L 1,760 1,073 40,955 2,304 62.1 (60.3 to 63.9) 94.7 (94.5 to 94.9) 43.3 (41.8 – 44.8) 97.5 (97.3 to 97.6) 
Primary symptom of chest pain (n=33,308) 
Uniform 99th 
percentile 





1,531 698 15,323 416 68.7 (66.7 to 70.6) 97.4 (97.1 to 97.6) 78.6 (76.8 to 80.4) 95.7 (95.3 -96.0) 
16 ng/L  
(women) 
1,172 993 12,990 195 54.1 (52.0 to 56.2) 98.5 (98.3 to 98.7) 85.7 (83.8 to 87.5) 92.9 (92.5 -93.3) 
Rule-in*  64 ng/L 1,847 733 29,271 1,468 71.6 (69.8 to 73.3) 95.2 (95.0 to 95.5) 55.7 (54.0 to 57.4) 97.6 (97.4 to 97.7) 
3-times URL 78 ng/L 1,727 632 29,372 1,588 73.2 (71.4 to 75.0) 94.9 (94.6 to 95.1) 52.1 (50.4 to 53.8) 97.9 (97.7 to 98.1) 
5-times URL 130 ng/L 1,388 447 29,557 1,927 75.6 (73.6 to 77.6) 93.9 (93.6 to 94.1) 41.9 (40.2 to 43.6) 98.5 (98.4 to 98.6) 
Presented as number or % (95% confidence intervals) as appropriate. * rule-in threshold recommended in the ESC 0/1 hour and 0/2 early rule-out and rule-in algorithms 11  










Figure 1. High-Sensitivity Cardiac Troponin I Concentrations at Presentation in Patients 
with Myocardial Injury and Infarction  
Kernel density plot of presentation troponin concentration stratified by the adjudicated diagnosis: 
type 1 myocardial infarction (red), type 2 myocardial infarction (yellow), acute myocardial 
injury (blue) and chronic myocardial injury (grey).  
 
Figure 2. Positive Predictive Value of High-Sensitivity Cardiac Troponin I Concentration 
at Presentation for a Diagnosis of Type 1 Myocardial Infarction  
Positive predictive value and 95% confidence intervals of high-sensitivity cardiac troponin I 
concentration at presentation for type 1 myocardial infarction in all patients with suspected acute 
coronary syndrome (blue) and in those with a primary symptom of chest pain (red). The dotted 
lines illustrate the positive predictive value of the uniform 99th percentile and 5-fold upper 
reference limit (URL). 
 
Figure 3. Kinetics of High-Sensitivity Cardiac Troponin I Concentration from Symptom 
Onset in Patients with Myocardial Injury and Infarction 
Spaghetti plot illustrating high-sensitivity cardiac troponin I concentrations in relation to the time 
of symptom onset in individual patients stratified by the adjudicated diagnosis: type 1 
myocardial infarction (red), type 2 myocardial infarction (yellow), acute myocardial injury (blue) 
and chronic myocardial injury (grey). The plot is restricted to those patients where any troponin 
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within 12 hours of presentation, and where the time of symptom onset was known (n=3,845). 
Linear mixed-effects modeling was done using random intercepts and random slopes, including  
quadratic terms for time, with cardiac troponin I as outcome. The output from a linear mixed-
effects model incorporating time from symptom onset, troponin and change in troponin 
concentration is overlaid for each condition. For each condition, the final model to estimate the 
trajectory of cardiac troponin I was chosen based on the Akaike Information Criteria. 
 
Figure 4. Absolute and Relative Change in High-Sensitivity Cardiac Troponin I 
Concentration on Serial Testing in Patients with Myocardial Injury and Infarction 
Violin-density and box and whisker plots illustrating the absolute and relative change in high-
sensitivity cardiac troponin I concentration on serial testing in patients stratified by the 
adjudicated diagnosis: type 1 myocardial infarction (red), type 2 myocardial infarction (yellow), 
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